Tuberculosis Therapeutics Market on Track for Strong Growth, Estimated to Grow at 6.2% CAGR Through 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Tuberculosis Therapeutics Market Through 2025?
A significant expansion has been observed in the market encompassing treatments for tuberculosis, demonstrating robust growth over the past few years, projected to increase from a value of $1.88 billion in 2024 to $2 billion the following year, which reflects a compounded annual growth rate of 6.6%; this upward trajectory during the past period is fundamentally linked to several factors, including a surge in tuberculosis cases, broader utilization of associated therapeutic agents, heightened public and medical community consciousness regarding TB, a mounting prevalence of extensively drug-resistant TB (XDR-TB), and a corresponding rise in the occurrence of tuberculosis strains that are resistant to existing medications.

What's the Projected Size of the Global Tuberculosis Therapeutics Market by 2029?
Anticipated robust expansion is projected for the tuberculosis medication sector over the upcoming years, with its valuation slated to reach $2.55 billion by 2029, reflecting a compound annual growth rate of 6.2%; this upswing during the projection timeframe is underpinned by several factors, such as heightened capital outlays directed towards medical facilities, escalating public consciousness and educational initiatives, augmented financial commitments to research endeavors, the securing of approvals for diverse anti-tuberculosis compounds, increased allocation of funds for scientific investigation, and a steadily aging global populace.

View the full report here:
https://www.thebusinessresearchcompany.com/report/tuberculosis-therapeutics-global-market-report

Top Growth Drivers in the Tuberculosis Therapeutics Industry: What's Accelerating the Market?
The anticipated escalation in co-infection prevalence involving tuberculosis and HIV is poised to act as a significant catalyst for the overall expansion of the tuberculosis therapeutics sector. This co-infection metric, representing those simultaneously affected by both TB and HIV, climbs because the immunosuppressive effects of HIV heighten vulnerability to tuberculosis, coupled with the widespread convergence of these two health crises within susceptible demographics globally. Treatments for tuberculosis play a crucial role in mitigating the impact of this dual burden by offering specific interventions that manage the TB infection alongside the immune deficiencies stemming from HIV, thereby enhancing clinical results and lessening the overall societal weight of both ailments. To illustrate this trend, official data from the UK public sector authority, gov.uk, indicated that new HIV diagnoses in England reached 3,805 across 2022, which signifies a notable 22 percent escalation compared to the 3,118 instances documented the preceding year in 2021. Consequently, the increasing incidence of TB-HIV co-infections is directly fueling the progression observed in the market for tuberculosis therapies.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20983&type=smp

What Trends Will Shape the Tuberculosis Therapeutics Market Through 2029 and Beyond?
Leading firms within the tuberculosis treatment sector are prioritizing the creation of novel approaches, notably combination regimens, with the goals of boosting therapeutic effectiveness, shortening the necessary treatment period, and overcoming resistance issues in tubercle bacilli. This strategy of combining two or more distinct classes of drugs aims to enhance overall treatment success, minimize the chances of resistance developing, and ultimately foster better results for individuals receiving care. A notable advancement in this area occurred in July 2024 when Johnson & Johnson, a pharmaceutical entity headquartered in the United States, secured dual endorsements from the US FDA and the European Commission for their product, SIRTURO (bedaquiline). What makes this pharmaceutical entity remarkable is that it stands as the initial medication in more than forty years specifically engineered to target tuberculosis strains resistant to multiple drugs (MDR-TB). Its distinctive operational principle involves impeding the ATP synthase enzyme, which is vital for the energy metabolism of TB bacteria, thus presenting a precise and potent method of intervention. When integrated into combination therapies, this drug notably boosts the overall potency of MDR-TB treatment plans, leading to shorter recovery timelines and better adherence from patients.

What Are the Main Segments in the Tuberculosis Therapeutics Market?
The tuberculosis therapeuticsmarket covered in this report is segmented -

1) By Type: Active Tuberculosis (TB); Latent Tuberculosis (TB)
2) By Product Type: Isoniazid; Rifampin; Pyrazinamide; Hydrazine derivatives; Miscellaneous anti-tubercular drugs; Ethambutol
3) By Route of Administration: Oral; Parenteral; Other route of administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users

Subsegments:
1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol); Second-Line Drugs (Fluoroquinolones, Aminoglycosides); Combination Therapies; Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis; Rifampicin-Based Regimens; Rifapentine-Based Regimens; Combination Prophylactic Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=20983&type=smp

Which Top Companies are Driving Growth in the Tuberculosis Therapeutics Market?
Major companies operating in the tuberculosis therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Macleods Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., Sequella Inc.

Which Regions Will Dominate the Tuberculosis Therapeutics Market Through 2029?
North America was the largest region in the tuberculosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tuberculosis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20983

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.